Review article: High-dose aminosalicylates to induce and maintain remissions in ulcerative colitis

Alimentary Pharmacology and Therapeutics

Volumn 24, Issue SUPPL. 3, 2006, Pages 37-40

  Hanauer, S B ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOSALICYLIC ACID; BALSALAZIDE; MESALAZINE; OLSALAZINE; SALAZOSULFAPYRIDINE; SPD 476; SULFAPYRIDINE;

CLINICAL TRIAL; DRUG FORMULATION; HUMAN; META ANALYSIS; PRIORITY JOURNAL; REMISSION; REVIEW; SYSTEMATIC REVIEW; ULCERATIVE COLITIS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLITIS, ULCERATIVE; DRUG ADMINISTRATION SCHEDULE; HUMANS; MESALAMINE; REMISSION INDUCTION; SULFASALAZINE; TREATMENT OUTCOME;

EID: 33748302766     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2006.03058.x     Document Type: Review

References (18)

1. Sutherland L, MacDonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2003: CD000543.
2. Sandborn WJ, Feagan BG, Hanauer SB, et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology 2002; 122: 512-30.
3. Cunliffe RN, Scott BB. Monitoring for drug side-effects in inflammatory bowel disease. Aliment Pharmacol Ther 2002; 16: 647-62.
4. Sandborn WJ, Hanauer SB. The pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. Aliment Pharmacol Ther 2003; 17: 29-42.
5. Sandborn WJ. Rational selection of oral 5-aminosalicylate formulations and pro-drugs for the treatment of ulcerative colitis. Am J Gastroenterol 2002; 97: 2939-41.
6. Mahadaven U, Sandborn WJ. Pharmacology of agents for ulcerative colitis. In: Sandborn WJ, Sartor R, eds. Kirsner's: Inflammatory Bowel Disease, 6th edn. Philadelphia: Saunders, 2004: 484-502.
7. Hanauer SB. Review Articles: Drug Therapy: Inflammatory Bowel Disease. N Engl J Med 1996; 334: 841-8.
8. Lim WC, Hanauer SB. Controversies with aminosalicylates in inflammatory bowel disease. Rev Gastroenterol Disord 2004; 4: 104-17.
9. Langholz E, Munkholm P, Nielsen OH, Kreiner S, Binder V. Incidence and prevalence of ulcerative colitis in Copenhagen county from 1962 to 1987. Scand J Gastroenterol 1991; 26: 1247-56.
10. Sutherland LR, Xiao LF. Clinical trial desgin with an emphasis on indices to measure disease activity. In: Sartor RB, Sandborn WJ, eds. Kirsner's Inflammatory Bowel Disease. 6th edn. Edinburgh: Saunders Publishing, 2004: 453-68.
11. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987; 317: 1625-9.
12. Hanauer S, Schwartz J, Robinson M, et al. Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group. Am J Gastroenterol 1993; 88: 1188-97.
13. Kruis W, Bar-Meir S, Feher J, et al. The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: A dose-finding study with newly developed mesalamine. Clinical Gastroenterology & Hepatology 2003; 1: 36-43.
14. Hanauer SB, Sandborn WJ, Kornbluth A, et al. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am J Gastroenterol 2005; 100: 2478-85.
15. Marteau P, Probert CS, Lindgren S, et al. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised controlled, double blind, placebo controlled study. Gut 2005; 54: 960-5.
16. Sands BE, Bank S, Sninsky CA, et al. Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn's disease. Gastroenterology 1999; 117: 58-64.
17. Marteau P, Probert CS, Lindgren S, et al. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study. Gut 2005; 54: 960-5.
18. PDR Staff. Thomson Healthcare. Physician's Desk Reference 2004; 1131: 2996.